FASEB BioAdvances · Nov 15, 2026

Dapagliflozin Mitigates Renal Fibrosis and Inflammation in Obese 5/6‐Nephrectomized Rats

By Bernardo DRD, Canale D, Nascimento MM et al.

Obesity is a chronic disease directly and indirectly related to the progression of chronic kidney disease. Sodium‐glucose cotransporter‐2 inhibitors like dapagliflozin offer new renal protection strategies beyond their glucose‐lowering properties. This study evaluated the effects of dapagliflozin on kidney impairment in obese rats subjected to 5/6 nephrectomy. Male Wistar rats (8 weeks old) were followed during a 100‐day protocol and submitted to Nx surgery on Day 40. The animals were randomly allocated to four groups according to the diet: standard (Nx); high‐fat (Nx + H); standard + dapagliflozin (Nx + D); and high‐fat +dapagliflozin (Nx + H + D). Dapagliflozin (50 mg/kg diet) treatment was administered daily after Nx surgery. Assessments included anthropometrics, inulin clearance, renal hemodynamics, biochemistry, immunohistochemistry, and protein expression for inflammation and fibrosis. Dapagliflozin treatment led to reduced body weight and abdominal circumference in the Nx + H + D. It also increased glycosuria and lowered plasma glucose. Crucially, dapagliflozin restored glomerular filtration rate and attenuated the renal expression of extracellular matrix proteins, inflammatory markers, and phenotypic alterations. This resulted in a lower kidney injury score compared to the Nx + H. In summary, dapagliflozin attenuated metabolic and anthropometric parameters and mitigated the progression of kidney disease in obese rats following a 5/6 nephrectomy insult.

doi.org/10.1096/fba.2026-00199Open accessInterventions

AgingResearch.News